To view this email as a web page, click here.
 
HIGHLIGHTS   |  June 14, 2019
 
Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for mCRPC
A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for mCRPC.
Read more
 
ADVERTISEMENT
Advertisement
Dr. Mehmet Sitki Copur on the Most Exciting Research Presented at ASCO 2019
Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist at the Morrison Cancer Center, about the most exciting research presented at ASCO in 2019.
Read more
 
IN CASE YOU MISSED IT
 
Long-Awaited Results of Isatuximab Combo in R/R Myeloma Presented
Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.